NCT05267041

Brief Summary

Prospective longitudinal cohort associated to blood collection, pathological samples collection, and radiological and pathological imaging collection.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4,000

participants targeted

Target at P75+ for not_applicable lung-cancer

Timeline
195mo left

Started May 2022

Longer than P75 for not_applicable lung-cancer

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress20%
May 2022May 2042

First Submitted

Initial submission to the registry

February 14, 2022

Completed
18 days until next milestone

First Posted

Study publicly available on registry

March 4, 2022

Completed
2 months until next milestone

Study Start

First participant enrolled

May 5, 2022

Completed
10 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 5, 2032

Expected
10 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 5, 2042

Last Updated

November 21, 2025

Status Verified

November 1, 2025

Enrollment Period

10 years

First QC Date

February 14, 2022

Last Update Submit

November 18, 2025

Conditions

Keywords

Data collectionlung cancer

Outcome Measures

Primary Outcomes (1)

  • Number of participants registered in the lung cancer database

    cohort open to recruitment during 10 years with 10 years of patients follow-up

    20 years

Study Arms (1)

Cohort of Adults with lung cancer

EXPERIMENTAL

Patients newly diagnosed with lung cancer.

Biological: Blood sampleOther: Questionnaire

Interventions

Blood sampleBIOLOGICAL

One optional veinous blood sampling (24 ML) between the first diagnostic annoucement and before the first treatment for lung cancer

Cohort of Adults with lung cancer

to collect data not reported in the patient's medical file, such as passive smoking, family history of cancer, and attempts to quit smoking.

Cohort of Adults with lung cancer

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient treated for a thoracic cancer in the Lyon University Hospital: non-small cell lung cancer, small cell lung cancer, mesothelioma…
  • Diagnosis can be done:
  • By cytology or pathologic assessment
  • Or by multidisciplinary team meeting decision:
  • Irradiation without morpho-metabolic sampling
  • Treatment without sampling based on non-invasive molecular data

You may not qualify if:

  • \- Refusal to participate
  • For optional blood sampling :
  • \< 30 kg for blood collection
  • No blood sampling schedule for care

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Hospitalier Lyon Sud

Pierre-Bénite, 69495, France

RECRUITING

MeSH Terms

Conditions

Lung Neoplasms

Interventions

Blood Specimen CollectionSurveys and Questionnaires

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative TechniquesData CollectionEpidemiologic MethodsHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Model Details: One questionnaire between diagnostic annoucement and first line treatement One 6 months later One before second line treatment One 6 months later after second line treatment Optionnal Veinous Blood Sample (28 mL) between the diagnostic annoucement and the first line of treatment
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 14, 2022

First Posted

March 4, 2022

Study Start

May 5, 2022

Primary Completion (Estimated)

May 5, 2032

Study Completion (Estimated)

May 5, 2042

Last Updated

November 21, 2025

Record last verified: 2025-11

Locations